Drug Profile
Milategrast - Eisai
Alternative Names: [14C]-E6007; E-6007Latest Information Update: 20 May 2022
Price :
$50
*
At a glance
- Originator Eisai Inc
- Developer EA Pharma; Eisai Inc
- Class Anti-inflammatories; Antiulcers; Piperazines; Small molecules
- Mechanism of Action Integrin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
- Discontinued Inflammatory bowel diseases; Ulcerative colitis
Most Recent Events
- 20 May 2022 Discontinued - Phase-II for Ulcerative colitis in Japan (PO), due to business priorities (EA Pharma, Eisai Co Ltd pipeline, May 2022)
- 28 May 2021 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in United Kingdom (PO)
- 18 Oct 2019 Discontinued - Phase-I for Inflammatory bowel diseases in USA (PO)